Streetbeat News

Analyst Ratings

AVIR

Concentra Biosciences, an affiliate of Tang Capital, has proposed to acquire Atea Pharmaceuticals (NASDAQ: AVIR) at $5.75 per share, a 55% premium to Friday's closing price. The deal is expected to close by July 2023. Tang Capital and Concentra have disclosed a 3.6% stake in Atea. William Blair maintains an Outperform rating for Atea.

Portfolio Pulse from Vandana Singh

May 22, 2023 | 9:37 pm

VST

Over the past 3 months, 5 analysts have published their opinion on Vistra (NYSE:VST) stock, with all 5 being somewhat bullish. The average 12-month price target for Vistra is $31.8, with a high of $35.00 and a low of $30.00. The average price target has increased by 1.92% over the past month.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 9:02 pm

CURI

Over the past 3 months, 4 analysts have published their opinion on CuriosityStream (NASDAQ:CURI) stock, with all 4 giving bullish ratings. The average 12-month price target is $2.5, representing a 54.55% decrease from the previous average of $5.50.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 9:02 pm

PCG

Analysts have provided various ratings for PG&E (NYSE:PCG) within the last quarter, with an average price target of $17.07, implying an upside from the current price of $16.505. The average price target has increased by 10.84% over the past month.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 9:01 pm

ULTA

Ulta Beauty (NASDAQ:ULTA) has received 16 analyst ratings in the last quarter, with an average price target of $588.94, implying an upside from the current price of $480.68. The current average has increased by 7.49% from the previous average price target of $547.92.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 9:01 pm

PGR

In the last 3 months, 17 analysts have offered 12-month price targets for Progressive (NYSE:PGR), with an average price target of $146.82, a high of $197.00, and a low of $118.00. The average price target has increased by 2.59% over the past month.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 9:00 pm

ARES

Over the past 3 months, 8 analysts have published their opinions on Ares Management (NYSE:ARES) stock, with an average price target of $98.88, implying an upside from the current price of $85.11. The current average has increased by 2.87% from the previous average price target of $96.12.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 9:00 pm

HD

A whale has taken a bullish stance on Home Depot (NYSE:HD) with 56% of investors opening trades with bullish expectations and 43% with bearish. Whales have been targeting a price range of $260 to $340 for Home Depot over the last 3 months. Several financial institutions maintain positive ratings on Home Depot with price targets ranging from $318 to $340.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 8:47 pm

TXN

A large investor has taken a bullish stance on Texas Instruments (NASDAQ:TXN), with 54% of big-money traders being bullish and 45% bearish. Whales have been targeting a price range of $160 to $180 for TXN over the last 3 months. Analysts from various firms have maintained their ratings on the company, with price targets ranging from $173 to $230.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 8:31 pm

ICPT

FDA's Gastrointestinal Drugs Advisory Committee voted against the benefits of Intercept Pharmaceutical's Ocaliva 25 mg for NASH patients with stage 2 or 3 fibrosis. HC Wainwright downgraded the stock to Sell from Neutral, citing potential commercial failure and competition from other drugs.

Portfolio Pulse from Vandana Singh

May 22, 2023 | 8:20 pm